HPV 检测和巴氏试验市场－全球产业规模、份额、趋势、机会和预测、细分测试类型、按应用、按最终用户、按地区和竞争情况，2020-2030 年预测

2024 年全球 HPV 检测和巴氏试验市场价值为 42.6 亿美元，预计到 2030 年将达到 80.1 亿美元，预测期内复合年增长率为 11.10%。随着世界各地的医疗保健系统更加关注女性健康和子宫颈癌的预防，该市场正在强劲扩张。人类乳突病毒 (HPV) 是导致子宫颈癌的主要原因，推动了对 HPV 检测和巴氏抹片等早期检测工具的需求。市场成长受到公众意识不断提高、政府筛检计画以及 HPV DNA 检测和液基细胞学等技术创新的支持，这些技术具有更高的灵敏度和更好的诊断准确性。这些进步增强了早期检测能力，减少了假阴性，并改善了患者的治疗效果。增加医疗保健投资、透过即时诊断方法扩大筛检管道以及优先采取预防性保健措施也做出了重大贡献。 COVID-19 疫情进一步加速了高效、可扩展诊断解决方案的采用，增强了可靠检测工具在全球医疗保健系统中的价值。

关键市场驱动因素

子宫颈癌发病率和死亡率上升

主要市场挑战

医疗服务取得机会有限

主要市场趋势

HPV DNA 检测的快速普及

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球HPV检测与巴氏试验市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依检测类型（HPV 检测、巴氏试验、联合检测）
  • 按应用（子宫颈癌筛检测试、头颈癌筛检测试、其他应用）
  • 依最终使用者（医院/诊所、诊断中心、护理点/自我采样）
  • 按公司分类（2024）
  • 按地区
• 市场地图

第六章：北美HPV检测与巴氏试验市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第七章：欧洲HPV检测与巴氏试验市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第 8 章：亚太地区 HPV 检测与巴氏试验市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲

第九章：南美HPV检测与巴氏试验市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲 HPV 检测和巴氏试验市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 併购

第 13 章： 大环境分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章：竞争格局

• Arbor Vita Corporation
• Danaher Corporation
• Seegene Inc.
• Becton, Dickinson and Company
• TruScreen
• Abbott Laboratories
• Hologic Inc.
• Qiagen NV
• F. Hoffmann-La Roche Ltd
• OncoHealth Corporation

第十六章：策略建议

第17章调查会社について・免责事项

The Global HPV Testing and Pap Test Market was valued at USD 4.26 billion in 2024 and is projected to reach USD 8.01 billion by 2030, growing at a CAGR of 11.10% during the forecast period. This market is witnessing robust expansion as healthcare systems around the world focus more on women's health and the prevention of cervical cancer. Human Papillomavirus (HPV), a primary cause of cervical cancer, has driven demand for early detection tools such as HPV testing and Pap smears. Market growth is being supported by rising public awareness, government screening programs, and technological innovations like HPV DNA testing and liquid-based cytology, which offer higher sensitivity and improved diagnostic accuracy. These advancements enhance early detection, reduce false negatives, and improve patient outcomes. Increasing healthcare investments, expanding screening access through point-of-care methods, and the prioritization of preventive health measures are also contributing significantly. The COVID-19 pandemic further accelerated the adoption of efficient and scalable diagnostic solutions, reinforcing the value of reliable testing tools in global healthcare systems.

Key Market Drivers

Rising Cervical Cancer Incidence and Mortality Rates

The growing incidence of cervical cancer, especially in low- and middle-income countries, is a primary factor driving the demand for HPV and Pap testing. Many of these regions face high mortality rates due to late diagnoses and limited access to routine screenings. According to the WHO, in 2020, around 604,000 women were diagnosed with cervical cancer globally, with 342,000 deaths. Given that a majority of these cases are linked to HPV infections, early screening using HPV tests and Pap smears has become vital. Governments and health organizations are expanding screening programs to address this urgent public health issue, with efforts ranging from public education campaigns to infrastructure development and subsidized testing services. The increasing focus on early detection as a means of reducing cervical cancer mortality is expected to significantly boost the adoption of HPV and Pap tests across diverse healthcare settings.

Key Market Challenges

Limited Access to Healthcare Services

Access to healthcare services remains a significant barrier to the widespread adoption of HPV and Pap testing, particularly in underserved and rural areas. In many regions, inadequate healthcare infrastructure, limited medical personnel, long travel distances to healthcare facilities, and affordability issues prevent regular screenings. Women in these settings are often unable to receive timely diagnostic evaluations, increasing the risk of undetected cervical abnormalities progressing to cancer. These systemic challenges reduce overall screening rates and limit the effectiveness of national and global cancer prevention efforts. Addressing these access issues is essential for ensuring that life-saving tests reach the populations most at risk.

Key Market Trends

Rapid Adoption of HPV DNA Testing

The increasing use of HPV DNA testing is a major trend reshaping the HPV and Pap test market. This advanced method offers superior sensitivity and specificity in identifying high-risk HPV strains that are most likely to cause cervical cancer. As awareness of its diagnostic advantages grows, healthcare providers are increasingly integrating HPV DNA tests into routine screening protocols. This trend is further accelerated by the rising demand for early and accurate detection tools, especially in preventive oncology. The shift towards HPV DNA testing is enhancing the reliability of screening programs and contributing to better patient outcomes by identifying risk at an earlier stage.

Key Market Players

• Arbor Vita Corporation
• Danaher Corporation
• Seegene Inc.
• Becton, Dickinson and Company
• TruScreen
• Abbott Laboratories
• Hologic Inc.
• Qiagen N.V.
• F. Hoffmann-La Roche Ltd
• OncoHealth Corporation

Report Scope:

In this report, the Global HPV Testing and Pap Test Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

HPV Testing and Pap Test Market, By Test Type:

• HPV Test
• Pap Test
• Co-testing

HPV Testing and Pap Test Market, By End User:

• Hospitals/Clinics
• Diagnostic Centers
• Point-of-Care/Self-sampling

HPV Testing and Pap Test Market, By Application:

• Cervical Cancer Screening Test
• Head and Neck Cancer Screening Test
• Other Applications

HPV Testing and Pap Test Market, By Region:

• North America
  • United States
  • Mexico
  • Canada
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global HPV Testing and Pap Test Market.

Available Customizations:

Global HPV Testing and Pap Test Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global HPV Testing and Pap Test Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (HPV Test, Pap Test, Co-testing)
  • 5.2.2. By Application (Cervical Cancer Screening Test, Head and Neck Cancer Screening Test, Other Applications)
  • 5.2.3. By End User (Hospitals/Clinics, Diagnostic Centers, Point-of-Care/Self-sampling)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America HPV Testing and Pap Test Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States HPV Testing and Pap Test Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Mexico HPV Testing and Pap Test Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Canada HPV Testing and Pap Test Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe HPV Testing and Pap Test Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France HPV Testing and Pap Test Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany HPV Testing and Pap Test Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom HPV Testing and Pap Test Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Test Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy HPV Testing and Pap Test Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain HPV Testing and Pap Test Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia-Pacific HPV Testing and Pap Test Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China HPV Testing and Pap Test Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India HPV Testing and Pap Test Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. South Korea HPV Testing and Pap Test Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. Japan HPV Testing and Pap Test Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia HPV Testing and Pap Test Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. South America HPV Testing and Pap Test Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil HPV Testing and Pap Test Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina HPV Testing and Pap Test Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia HPV Testing and Pap Test Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Middle East and Africa HPV Testing and Pap Test Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa HPV Testing and Pap Test Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia HPV Testing and Pap Test Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE HPV Testing and Pap Test Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Arbor Vita Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Danaher Corporation
• 15.3. Seegene Inc.
• 15.4. Becton, Dickinson and Company
• 15.5. TruScreen
• 15.6. Abbott Laboratories
• 15.7. Hologic Inc.
• 15.8. Qiagen N.V.
• 15.9. F. Hoffmann-La Roche Ltd
• 15.10. OncoHealth Corporation

16. Strategic Recommendation

17. About Us & Disclaimer